[go: up one dir, main page]

ECSP088573A - Triazolopiridazinas como moduladores de tirosina cinasa - Google Patents

Triazolopiridazinas como moduladores de tirosina cinasa

Info

Publication number
ECSP088573A
ECSP088573A EC2008008573A ECSP088573A ECSP088573A EC SP088573 A ECSP088573 A EC SP088573A EC 2008008573 A EC2008008573 A EC 2008008573A EC SP088573 A ECSP088573 A EC SP088573A EC SP088573 A ECSP088573 A EC SP088573A
Authority
EC
Ecuador
Prior art keywords
compounds
met
cell
subject
modulators
Prior art date
Application number
EC2008008573A
Other languages
English (en)
Inventor
Robert A Galemmo
Robert W Tuman
Dana L Johnson
Maxwell David Cummings
Tianbao Lu
Richard Alexander
Richard W Connors
Heather Rae Hufnagel
Ehab Khalil
Kristi A Leonard
Thomas P Markotan
Anna C Maroney
Jan L Sechler
Jeremy M Travins
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088573(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP088573A publication Critical patent/ECSP088573A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)

Abstract

La invención está dirigida a compuestos de triazolopiridazina de la fórmula (I):en donde R1, R5, R6, R7, R8, y A son como se define aquí, el uso de dichos compuestos como moduladores de proteína tirosina cinasa, particularmente inhibidores de c-Met, y el uso de dichos compuestos para reducir o inhibir la actividad de cinasa de c-Met en una célula o un sujeto, y modular la expresión de c-Met en una célula o un sujeto, y el uso de dichos compuestos para prevenir o tratar en un sujeto un trastorno proliferativo de células y/o trastornos relacionados con c-Met; la presente invención está dirigida además a composiciones farmacéuticas que comprenden los compuestos de la presente invención y a métodos para tratar condiciones tales como cánceres y otros trastornos proliferativos de células.
EC2008008573A 2005-12-21 2008-06-20 Triazolopiridazinas como moduladores de tirosina cinasa ECSP088573A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75263405P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
ECSP088573A true ECSP088573A (es) 2008-07-30

Family

ID=37964498

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008573A ECSP088573A (es) 2005-12-21 2008-06-20 Triazolopiridazinas como moduladores de tirosina cinasa

Country Status (40)

Country Link
US (2) US8030305B2 (es)
EP (1) EP1966214B9 (es)
JP (1) JP5292102B2 (es)
KR (1) KR101412675B1 (es)
CN (1) CN101374843B (es)
AP (1) AP3433A (es)
AR (1) AR058703A1 (es)
AU (1) AU2006331912B2 (es)
BR (1) BRPI0620292B1 (es)
CA (1) CA2634721C (es)
CR (1) CR10170A (es)
CY (1) CY1118846T1 (es)
DK (1) DK1966214T3 (es)
EA (1) EA015754B1 (es)
EC (1) ECSP088573A (es)
ES (1) ES2612377T3 (es)
GT (1) GT200800105A (es)
HN (1) HN2008000931A (es)
HR (1) HRP20170103T1 (es)
HU (1) HUE030390T2 (es)
IL (1) IL192108A (es)
LT (1) LT1966214T (es)
MA (1) MA30084B1 (es)
ME (1) ME02736B (es)
MX (1) MX2008008277A (es)
MY (1) MY159523A (es)
NI (1) NI200800179A (es)
NO (1) NO340958B1 (es)
NZ (1) NZ568807A (es)
PE (2) PE20070752A1 (es)
PL (1) PL1966214T3 (es)
PT (1) PT1966214T (es)
RS (1) RS55630B1 (es)
SV (1) SV2008002963A (es)
TN (1) TNSN08278A1 (es)
TW (1) TWI399378B (es)
UA (1) UA98297C2 (es)
UY (1) UY30041A1 (es)
WO (1) WO2007075567A1 (es)
ZA (1) ZA200806277B (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1824340A4 (en) * 2004-12-17 2009-08-05 Bionovo Inc PROCESS FOR USING EXTRACTS OF SPECIES OF THE GENUS EPIMEDIUM
US7482029B2 (en) 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
PL3091011T3 (pl) 2006-04-07 2018-06-29 Vertex Pharmaceuticals Incorporated Modulatory transporterów posiadających kasetę wiążącą ATP
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
JP2009538899A (ja) * 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
DK2081937T3 (da) * 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Triazolopyridazin-proteinkinasemodulatorer
AU2007310787A1 (en) 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv A method for profiling kinase inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP3034075B1 (en) 2006-11-22 2018-07-25 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
WO2008155378A1 (en) * 2007-06-21 2008-12-24 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US8092841B2 (en) * 2007-08-08 2012-01-10 Bionovo, Inc. Estrogenic extracts of Ligustrum lucidum ait. of the oleaceae family and uses thereof
FR2929613B1 (fr) * 2008-04-02 2010-12-31 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
US20090068298A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. ESTROGENIC EXTRACTS OF Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family AND USES THEREOF
EP2203178A4 (en) * 2007-09-07 2012-03-21 Bionovo Inc ESTROGENEXTRACTS FROM PUERARIA LOBATA WILLD, OHWI FROM THE FAMILY OF LEGUMINOSAE AND APPLICATIONS THEREOF
CA2698719A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of asparagus conchinchinensis (lour.) merr of the liliaceae family and uses thereof
EP2190292A4 (en) * 2007-09-07 2012-12-26 Bionovo Inc ESTROGENWIRKSAME EXTRACTS OF SCUTTELARIA BARBATA D. DON OF THE FAMILY LABIATAE AND ITS USES
WO2009070478A2 (en) * 2007-11-19 2009-06-04 Bionovo, Inc. A process of making purified extract of scutellaria barbata d. don
CA2706326A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
CA2706315A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Anti-cancer therapy with an extract of scutellaria barbata
US8512961B2 (en) * 2007-11-19 2013-08-20 Bionovo, Inc. Methods of detecting and treatment of cancers using Scutellaria barbata extract
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
ES2603302T3 (es) * 2008-02-05 2017-02-24 Sanofi Imidazopiridazinas como inhibidores de PAR1, su obtención y empleo como medicamento
NZ587142A (en) 2008-02-05 2012-04-27 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
JP5526040B2 (ja) * 2008-02-05 2014-06-18 サノフイ Ｐａｒ１阻害剤としてのトリアゾロピリダジン類、その製造法および薬剤としての使用
AU2009218459A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
US20090258942A1 (en) * 2008-04-14 2009-10-15 Bionovo, Inc. Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
CA2723403A1 (en) * 2008-05-06 2009-11-12 Bionovo, Inc. Estrogenic extracts for use in treating vaginal and vulvar atrophy
CA2724742C (en) 2008-05-21 2016-07-19 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
CA2726982A1 (en) * 2008-06-05 2009-12-10 Bionovo, Inc. Method of quantification of multiple bioactives from botanical compositions
EP2303249A4 (en) * 2008-06-06 2012-05-30 Bionovo Inc ANTHRAQUINONES AND ANALOGS FROM RHEUM PALMATUM FOR THE TREATMENT OF MEDIA CONDITIONS BY THE STROGEN BETA RECEPTOR
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
BRPI0916464A2 (pt) * 2008-07-18 2018-06-12 Sanofi-Aventis derivados triazolo(4,3-a) piridina, o respectivo processo de preparo, a respectiva aplicação como medicamentos, composições farmacêuticas e utilização notadamente como inibidores de met
FR2941229B1 (fr) * 2009-01-21 2012-11-30 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
US20100069480A1 (en) * 2008-09-03 2010-03-18 Bionovo, Inc. A Delaware Corporation Methods and compositions for the treatment of cancer
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
EA019320B1 (ru) 2008-12-22 2014-02-28 Мерк Патент Гмбх Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2010104843A2 (en) * 2009-03-09 2010-09-16 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
EP2424555A4 (en) * 2009-04-28 2013-02-20 Bionovo Inc METHOD FOR REDUCING FAT COLLECTION AND CAUSING WEIGHT LOSS
US8389526B2 (en) * 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CN102548995B (zh) * 2009-08-12 2015-01-28 诺华股份有限公司 杂环腙化合物以及它们治疗癌症和炎症的用途
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
HUE052828T2 (hu) 2009-12-31 2021-05-28 Hong Jia Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN103038214B (zh) * 2010-04-22 2015-09-30 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
KR101538707B1 (ko) * 2010-07-14 2015-07-22 베타 파머수티컬 컴퍼니 리미티드 c-MET 티로신 키나제 억제제로서 유용한 신규 융합된 헤테로사이클릭 유도체
BR112013000925A2 (pt) 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012158658A1 (en) 2011-05-16 2012-11-22 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
KR20130091464A (ko) * 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
MX2014011987A (es) 2012-04-03 2014-11-10 Novartis Ag Combinaciones de inhibidores de cinasa de tirosina y su uso.
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
WO2014017643A1 (ja) * 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CN104250257B (zh) * 2013-06-25 2017-06-16 上海翰森生物医药科技有限公司 3,4‑二氢‑1H‑苯并[c][1,2]噁硼酸类化合物或其可药用盐及其制备方法和用途
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
KR102479693B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 조합물
EP3122359B1 (en) 2014-03-26 2020-12-16 Astex Therapeutics Ltd. Combinations of an fgfr inhibitor and an igf1r inhibitor
HRP20230709T1 (hr) 2014-04-15 2023-10-13 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci za liječenje bolesti povezanih s regulatorom provodljivosti transmembrane cistične fibroze
TWI695837B (zh) * 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
US10231972B2 (en) * 2014-12-11 2019-03-19 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106279176B (zh) * 2015-06-11 2020-09-08 中国科学院上海药物研究所 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
MX2017016875A (es) 2015-06-26 2018-04-24 Takeda Pharmaceuticals Co Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico colinergico m1.
EP3353177B1 (en) 2015-09-23 2020-06-03 Janssen Pharmaceutica NV Tricyclic heterocycles for the treatment of cancer
MX378230B (es) 2015-09-23 2025-03-10 Janssen Pharmaceutica Nv 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer.
US10301325B2 (en) 2015-09-24 2019-05-28 Shanghai Haiju Biological Technology Co., Ltd. Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
WO2018033448A1 (de) * 2016-08-16 2018-02-22 Bayer Cropscience Aktiengesellschaft Verfahren zur herstellung von 2-(3,6-dihalopyridin-2-yl)-3h-imidazol[4,5-c]pyridinderivaten und verwandten verbindungen durch umsetzung des 3h-imidazol[4,5-c]pyridinderivats mit einer metallorganischen zink-amin base
EP3548033B1 (en) 2016-11-28 2024-04-10 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
TWI774755B (zh) * 2017-04-28 2022-08-21 日商佐藤製藥股份有限公司 二氟甲烯化合物之製造法
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019201718A1 (en) * 2018-04-18 2019-10-24 Basf Se D-glucaro-6,3-lactone monoester and a process for the preparation thereof
AU2019278814A1 (en) 2018-05-30 2020-12-17 Praxis Precision Medicines, Inc. Ion channel modulators
CN109045036B (zh) * 2018-07-19 2020-10-02 中山大学 [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用
EA202191541A1 (ru) 2018-12-14 2022-01-21 Бета Фарма, Инк. ЗАМЕЩЕННЫЕ ФОСФОРОРГАНИЧЕСКИМИ ГРУППАМИ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET И ИХ ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
CN110156805B (zh) * 2019-05-22 2020-12-11 南京合巨药业有限公司 一种2, 3-二氢-1, 4-二氧代[2,3-b]吡啶-7-羧酸的制备方法
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
WO2021222045A1 (en) * 2020-04-26 2021-11-04 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
TWI728882B (zh) 2020-07-28 2021-05-21 祥昇機電工業有限公司 自吸式抽水機之釋氣機構
WO2024032647A1 (zh) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
WO2025007275A1 (zh) * 2023-07-04 2025-01-09 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US192696A (en) * 1877-07-03 Improvement in combined cut-off and filter
US261297A (en) * 1882-07-18 Mortar for stamp-mills
US16625A (en) * 1857-02-10 Arraitg-ement of springs for vehicles
US147568A (en) * 1874-02-17 Improvement in paper-folding attachments for printing-presses
US111495A (en) * 1871-01-31 Stinb
US138264A (en) * 1873-04-29 Improvement in machines for cutting out planchets of sheet metal
US96322A (en) * 1869-11-02 Improvement in combined cultivator and seed-planter
US181455A (en) * 1876-08-22 Improvement in brooms
US171798A (en) * 1876-01-04 Improvement in spring attachments for cradles
US17309A (en) * 1857-05-12 Portable gas co
NL128591C (es) 1965-07-02
US3506656A (en) * 1966-10-22 1970-04-14 Boehringer Mannheim Gmbh Triazolo-tetrazolo-pyridazine derivatives
NL130097C (es) 1966-10-22
DE2222834A1 (de) 1972-05-10 1973-11-29 Boehringer Mannheim Gmbh Nitrofuryl-amidin-derivate und verfahren zur herstellung derselben
US3823137A (en) * 1970-06-20 1974-07-09 Boehringer Mannheim Gmbh Novel nitrofuran compounds and pharmaceutical compositions
DE2030581A1 (de) 1970-06-20 1971-12-30 Boehringer Mannheim GmbH, 6800 Mannheim-Waldhof Nitrofuryl-amidin-Derivate und Verfahren zur Herstellung derselben
GB1324060A (en) 1971-03-19 1973-07-18 Boehringer Mannheim Gmbh Nitrofuryl-triazolo 4,3-b pyridazine derivatives
DE2113438A1 (de) 1971-03-19 1972-09-21 Boehringer Mannheim Gmbh Nitrofuryl-triazolo[4,3-b]pyridazinderivate
DE2161587A1 (de) 1971-12-11 1973-06-14 Boehringer Mannheim Gmbh Nitrofuryl-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazinderivat
DE2147013A1 (de) * 1971-09-21 1973-03-29 Boehringer Mannheim Gmbh Antimikrobiell wirksame nitrofuranderivate und verfahren zur herstellung derselben
JPS5612390A (en) * 1979-07-10 1981-02-06 Yoshitomi Pharmaceut Ind Ltd Triazolopyridazine derivative
US4260755A (en) * 1979-10-31 1981-04-07 American Cyanamid Company Novel 6-phenyl and substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines
FR2562071B1 (fr) * 1984-03-30 1986-12-19 Sanofi Sa Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
AU622330B2 (en) * 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
US5278161A (en) * 1990-06-28 1994-01-11 Hoffmann-La Roche Inc. Amino acid derivatives useful as renin inhibitors
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
JPH06331089A (ja) 1993-05-18 1994-11-29 Asahi Organic Chem Ind Co Ltd プラスチック管の電気溶着方法
TW304878B (es) 1993-09-21 1997-05-11 Takeda Pharm Industry Co Ltd
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth Beschichteter dilatator zur abgabe eines arzneistoffs
US20020111495A1 (en) * 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6297235B1 (en) * 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
GB9718254D0 (en) * 1997-08-28 1997-11-05 Merck Sharp & Dohme Therapeutic agents
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
WO1999037644A1 (en) * 1998-01-21 1999-07-29 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
CN101073668A (zh) * 1999-04-28 2007-11-21 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
IL149550A0 (en) * 1999-11-12 2002-11-10 Neurogen Corp Bicyclic and tricyclic heteroaromatic compounds
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
EP1229034B1 (en) 2001-01-31 2005-04-13 Pfizer Products Inc. Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EP1383762B1 (fr) * 2001-04-20 2007-06-20 Sanofi-Aventis Tetrahydropyridyl-alkyl-heterocycles, procede pour leur preparation et compositions pharmaceutiques les contenants
JP2005509616A (ja) 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
CN1281606C (zh) * 2002-03-01 2006-10-25 安斯泰来制药有限公司 含氮杂环化合物
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6793457B2 (en) * 2002-11-15 2004-09-21 General Electric Company Fabricated repair of cast nozzle
MXPA05006478A (es) * 2002-12-18 2005-09-08 Vertex Pharma Triazolopiridazinas como inhibidores de proteinas cinasas.
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
JPWO2005002590A1 (ja) * 2003-07-01 2006-08-10 アステラス製薬株式会社 骨量増加誘導剤
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
EP1643836A4 (en) 2003-07-02 2006-12-06 Sugen Inc ARYLMETHYL TRIAZOLO AND IMIDAZOPYRAZINE C-MET INHIBITORS
US7037909B2 (en) * 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
CA2630884A1 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
JP2009538899A (ja) 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso

Also Published As

Publication number Publication date
IL192108A (en) 2014-02-27
ME02736B (me) 2017-10-20
US20090098181A1 (en) 2009-04-16
EP1966214B1 (en) 2016-11-02
AR058703A1 (es) 2008-02-20
AU2006331912B2 (en) 2012-08-30
RS55630B1 (sr) 2017-06-30
SV2008002963A (es) 2010-01-18
MX2008008277A (es) 2009-03-04
KR20080085154A (ko) 2008-09-23
JP5292102B2 (ja) 2013-09-18
NO20083013L (no) 2008-09-19
NO340958B1 (no) 2017-07-31
JP2009525263A (ja) 2009-07-09
EA015754B1 (ru) 2011-12-30
AP3433A (en) 2015-10-31
TNSN08278A1 (en) 2009-10-30
HUE030390T2 (en) 2017-05-29
LT1966214T (lt) 2017-02-10
BRPI0620292A2 (pt) 2011-11-08
EA200870085A1 (ru) 2008-12-30
EP1966214B9 (en) 2017-09-13
CY1118846T1 (el) 2018-01-10
CN101374843B (zh) 2012-09-05
EP1966214A1 (en) 2008-09-10
MA30084B1 (fr) 2008-12-01
US8173654B2 (en) 2012-05-08
NZ568807A (en) 2011-05-27
CR10170A (es) 2008-11-24
CA2634721A1 (en) 2007-07-05
ES2612377T3 (es) 2017-05-16
GT200800105A (es) 2008-10-10
NI200800179A (es) 2016-01-06
HRP20170103T1 (hr) 2017-03-24
PE20110008A1 (es) 2011-01-31
TW200801007A (en) 2008-01-01
CN101374843A (zh) 2009-02-25
PE20070752A1 (es) 2007-08-13
IL192108A0 (en) 2008-12-29
PT1966214T (pt) 2017-02-03
AP2008004502A0 (en) 2008-06-30
KR101412675B1 (ko) 2014-07-03
US20070203136A1 (en) 2007-08-30
UY30041A1 (es) 2007-05-31
CA2634721C (en) 2014-06-17
UA98297C2 (en) 2012-05-10
AU2006331912A1 (en) 2007-07-05
US8030305B2 (en) 2011-10-04
BRPI0620292B1 (pt) 2021-08-24
HN2008000931A (es) 2013-10-22
DK1966214T3 (en) 2017-02-13
MY159523A (en) 2017-01-13
ZA200806277B (en) 2010-09-29
PL1966214T3 (pl) 2017-04-28
WO2007075567A1 (en) 2007-07-05
TWI399378B (zh) 2013-06-21

Similar Documents

Publication Publication Date Title
ECSP088573A (es) Triazolopiridazinas como moduladores de tirosina cinasa
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
UY29588A1 (es) Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina
NI200700311A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
EA201290103A1 (ru) Гетероциклические соединения и их использование
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
MX2017007114A (es) Una triazolopiridazina como un modulador de cinasa.
EA200702136A1 (ru) Композиции станнсопорфина и их применение
CL2022003453A1 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2.
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
AR102887A1 (es) Una triazolopiridazina como modulador de quinasa